Rubella cases in Southeast Asia have been on the increase in recent years. Most regional countries however, are unable to produce their own vaccine against the disease. As part of their strategy, JICA and Kitasato Daiichi Sankyo Company aim to assist developing countries improve maternal and child health with lower incidence rates of infectious using technology from Japan. The government of Vietnam has worked to improve immunization rates for vaccines to prevent polio, measles, diphtheria, pertussis, tetanus and tuberculosis as part of its effort to lower the mortality rate for children up to 5 years of age under the National Expanded Programme on Immunization in Vietnam.
The Kitasato Institute Research Center for Biologicals (current Kitasato Daiichi Sankyo Vaccine) and JICA offered technical assistance to Vietnam's public corporation Center for Research and Production of Vaccines and Biologicals (POLYVAC) to produce the measles vaccine for four years between March 2006 and March 2010. As a result of this cooperation, POLYVAC has acquired technology for domestic production of measles vaccine. The 2013 technical cooperation project utilizes the rubella vaccine production technology of Kitasato Daiichi Sankyo Vaccine, in addition to the existing measles vaccine production technology of POLYVAC, to build a current Good Manufacturing Practice compliant measles-rubella combined vaccine production system that is expected to contribute to lowering the rate of measles and rubella cases in Vietnam.
|Location||Viet Nam, East Asia and Pacific|